These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23158694)

  • 21. A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
    Dulak-Lis M; Bujak A; Gala K; Banach M; Kędzierska U; Miszkiel J; Hucz-Kalitowska J; Mroczkiewicz M; Stypik B; Szymczak K; Gunerka P; Dubiel K; Zygmunt BM; Wieczorek M; Pieczykolan JS
    J Pharmacol Sci; 2021 Apr; 145(4):340-348. PubMed ID: 33712286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases.
    Ghosh D; Tsokos GC
    Autoimmunity; 2010 Feb; 43(1):48-55. PubMed ID: 20001666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell receptor-associated protein tyrosine kinases: the dynamics of tolerance regulation by phosphorylation and its role in systemic lupus erythematosus.
    Barrera-Vargas A; Gómez-Martín D; Alcocer-Varela J
    Hum Immunol; 2014 Sep; 75(9):945-52. PubMed ID: 25173412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.
    Shao WH; Cohen PL
    Expert Rev Clin Immunol; 2014 May; 10(5):573-82. PubMed ID: 24678775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinase inhibitors: a new class of antirheumatic drugs.
    Kyttaris VC
    Drug Des Devel Ther; 2012; 6():245-50. PubMed ID: 23055694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells.
    Krishnan S; Juang YT; Chowdhury B; Magilavy A; Fisher CU; Nguyen H; Nambiar MP; Kyttaris V; Weinstein A; Bahjat R; Pine P; Rus V; Tsokos GC
    J Immunol; 2008 Dec; 181(11):8145-52. PubMed ID: 19018007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Syk inhibitors].
    Kimura Y; Chihara K; Takeuchi K; Sada K
    Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Getting Syk: spleen tyrosine kinase as a therapeutic target.
    Geahlen RL
    Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-cell subsets, signaling and their roles in secretion of autoantibodies.
    Iwata S; Tanaka Y
    Lupus; 2016 Jul; 25(8):850-6. PubMed ID: 27252261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
    Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
    Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
    Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
    Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV.
    Ichinose K; Juang YT; Crispín JC; Kis-Toth K; Tsokos GC
    Arthritis Rheum; 2011 Feb; 63(2):523-9. PubMed ID: 20954187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Y-27632, a Rho-associated protein kinase inhibitor, inhibits systemic lupus erythematosus.
    Wang Y; Lu Y; Chai J; Sun M; Hu X; He W; Ge M; Xie C
    Biomed Pharmacother; 2017 Apr; 88():359-366. PubMed ID: 28122300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.